CFRX Stock Overview
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
ContraFect Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.069 |
| 52 Week High | US$13.02 |
| 52 Week Low | US$0.043 |
| Beta | 0.65 |
| 11 Month Change | -72.99% |
| 3 Month Change | -91.08% |
| 1 Year Change | -99.39% |
| 33 Year Change | -99.98% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Contrafect GAAP EPS of -$0.46 misses by $0.13
Aug 15ContraFect sinks ~76% as data safety board recommends ending co's DISRUPT trial
Jul 13ContraFect (NASDAQ:CFRX) Is In A Good Position To Deliver On Growth Plans
Jun 29
Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?
Dec 25ContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market
Sep 15We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate
Aug 18Is ContraFect (NASDAQ:CFRX) In A Good Position To Deliver On Growth Plans?
May 01Are Institutions Heavily Invested In ContraFect Corporation's (NASDAQ:CFRX) Shares?
Mar 09Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?
Jan 15What Type Of Shareholders Make Up ContraFect Corporation's (NASDAQ:CFRX) Share Registry?
Nov 24Contrafect EPS beats by $0.16
Nov 13Shareholder Returns
| CFRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 14.2% | 2.5% | 1.0% |
| 1Y | -99.4% | 15.6% | 31.4% |
Return vs Industry: CFRX underperformed the US Biotechs industry which returned -3.5% over the past year.
Return vs Market: CFRX underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| CFRX volatility | |
|---|---|
| CFRX Average Weekly Movement | 27.3% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CFRX's share price has been volatile over the past 3 months.
Volatility Over Time: CFRX's weekly volatility (27%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 23 | Mike Messinger | www.contrafect.com |
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections.
ContraFect Corporation Fundamentals Summary
| CFRX fundamental statistics | |
|---|---|
| Market cap | US$676.12k |
| Earnings (TTM) | -US$24.14m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs CFRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CFRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$24.14m |
| Earnings | -US$24.14m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CFRX perform over the long term?
See historical performance and comparison